topic

904 A case report of metastatic castration resistant prostate cancer patient with AR F877L mutation treated with KPG-121 in combination with enzalutamide
Alfredo Torres, Richard Zuniga, Chuansheng Ge, Baisong Liao, Yao Wang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1006; DOI: 10.1136/jitc-2023-SITC2023.0904
774 NeoPOWER: A phase II study of neoadjuvant PD-1 blockade with cemiplimab in high risk localized, locally recurrent and regionally advanced cutaneous squamous cell carcinoma
Gino K In, Sunandana Chandra, Jeffrey Sosman, Erin Barrett, Ashley Wysong, Alissa Marr, Joshua Mammen, Jacob Thomas, Thomas Won, Anisa Sandin, Sophia Marmolejo, Andrew Zeng, Fumito Ito, Niels Kokot, Mark Swanson, Daniel Kwon, Denice Tsao-Wei, Susan Groshen, Kevin Kelly, Hugo Lara Martinez, Andy Sherrod, Brittney Declerck, Gene Kim, David Peng, Jenny C Hu

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A871; DOI: 10.1136/jitc-2023-SITC2023.0774
775 Phase Ib/II Study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint Inhibitor therapy with and without CNS disease
Saya Jacob, Markee Micu, Zoe Quandt, Katy K Tsai, Shahriar Yaghoubi, Adil Daud

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A872; DOI: 10.1136/jitc-2023-SITC2023.0775
776 Long-term efficacy and safety of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: a 4-year analysis of the C-144–01 study
Theresa Medina, Jason A Chesney, Eric Whitman, Harriet Kluger, Sajeve Thomas, Amod A Sarnaik, John M Kirkwood, James Larkin, Jeffrey Weber, Omid Hamid, Martin Wermke, Friedrich Graf Finckenstein, Jeffrey Chou, Brian Gastman, Giri Sulur, Xiao Wu, Wen Shi, Evidio Domingo-Musibay

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A873; DOI: 10.1136/jitc-2023-SITC2023.0776
777 Initial results from an open-label phase 1b/2 study of RP1 oncolytic immunotherapy in solid organ and hematopoietic cell transplant recipients with advanced cutaneous malignancies (ARTACUS)
Michael R Migden, Wanxing Chai-Ho, Gregory A Daniels, Trisha M Wise-Draper, Meenal Kheterpal, Jennifer C Tang, Diana Bolotin, Claire Verschraegen, Andrew S Poklepovic, Shaheer A Khan, Sherrif F Ibrahim, Nathalie C Zeitouni, Theresa Medina, Katy K Tsai, Chris Tucci, Susan Navia, Laxminarasimha Donthireddy, Praveen K Bommareddy, Jeannie W Hou, Diwakar Davar

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A874; DOI: 10.1136/jitc-2023-SITC2023.0777
778 TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-naïve unresectable or metastatic melanoma
Daniel J Olson, James Larkin, Young Hong, Sajeve Thomas, Juan Martin-Liberal, Andrew JS Furness, Patrick Terheyden, Gino K In, Andrew S Poklepovic, Yazan Samhouri, Philip Lammers, Victoria Atkinson, Ryan H Nguyen, Idit Peretz, Marcus Butler, Friedrich Graf Finckenstein, Jeffrey Chou, Xiao Wu, Giri Sulur, Wen Shi, John B Haanen

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A875; DOI: 10.1136/jitc-2023-SITC2023.0778
779 A phase 1/2, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors
Martin Gutierrez, Elena Garralda, Emiliano Calvo, Marloes van Dongen, Ferry Eskens, Morgan Finlay, Fatima Menas, Chen Zhu, Meijing Wu, Helene Guillemin-Paveau, Giovanni Abbadessa, Raymond Perez, Ozlem Yildirim, Aung Naing

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A876; DOI: 10.1136/jitc-2023-SITC2023.0779
780 VISTA-101 – A phase 1/2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA, alone and in combination with pembrolizumab in advanced solid tumors
Shawn Iadonato, Yulia Ovechkina, Kurt Lustig, Vinny Hayreh, Thierry Guillaudeux

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A877; DOI: 10.1136/jitc-2023-SITC2023.0780
781 A phase II, open-label trial of bintrafusp alfa (M7824) in subjects with thymoma and thymic carcinoma (trial in progress)
Meredith McAdams, Shannon Swift, Renee N Donahue, Carolina Celades, Yo-Ting Tsai, Molly Bingham, Eva Szabo, Nirmal Choradia, Chen Zhao, Susan Sansone, Christine Feierabend, Meenakshi Shelat, Seth M Steinberg, Jeffrey Schlom, James L Gulley, Arun Rajan

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A878; DOI: 10.1136/jitc-2023-SITC2023.0781
782 TransCon TLR7/8 agonist induces sustained local and systemic immune activation in patients with solid tumors
Diwakar Davar, Mette Kriegbaum, Morteza Aghmesheh, Alain Algazi, David Bajor, Vinod Ganju, Douglas Laux, Alexander I Spira, Christian Krapp, Telma Lança, Joan Morris, Stina Singel, Thomas Tuxen Poulsen, Vibeke Miller Breinholt, Nashat Gabrail

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A879; DOI: 10.1136/jitc-2023-SITC2023.0782

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages